Clinical trial NCT05874141: Comorbidities in Type 2 Diabetes Mellitus
Official title: Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, Egypt
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: New Valley University
Sponsor class: OTHER
First posted: 2023-05-24
Enrollment: 288
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today

Detailed description: All-cause mortality rates have declined substantially in several high-income countries, including England.

A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex.

Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially.

Many studies have primarily focused on identifying multimorbidity patterns in the general population.

The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.

Eligibility criteria: Inclusion Criteria:

* Patients with type 2 diabetes.

Exclusion Criteria:

1. Patients with type 1 diabetes.
2. Patients with secondary diabetes.

Primary outcomes:
measure: Number of participants with hypertension
timeFrame: At time of inclusion in the study
measure: Number of participants with dyslipidemia
timeFrame: At time of inclusion in the study
measure: Number of participants with Diabetic kidney disease
timeFrame: At time of inclusion in the study
measure: Number of participants with Coronary heart disease
timeFrame: At time of inclusion in the study
measure: Number of participants with thyroid disorder
timeFrame: At time of inclusion in the study
measure: Number of participants with Stroke
timeFrame: At time of inclusion in the study
measure: Number of participants with Peripheral arterial disease
timeFrame: At time of inclusion in the study
measure: Number of participants with Diabetic eye disease
timeFrame: At time of inclusion in the study
measure: Number of participants with Peripheral neuropathy
timeFrame: At time of inclusion in the study
measure: Number of participants with Liver disease
timeFrame: At time of inclusion in the study
measure: Number of participants with Infections
timeFrame: At time of inclusion in the study
measure: Number of participants with Cancer
timeFrame: At time of inclusion in the study
Secondary outcomes:
measure: Number of participants with controlled diabetes mellitus with correlation to the number of cormobidity
timeFrame: At time of inclusion in the study
measure: Correlate the presence of each co-morbidity with the extent of diabetes control
timeFrame: At time of inclusion in the study
Other outcomes:
Locations:
city: Kharga Oasis
country: Egypt
facility: New Valley University
Study officials:
References:
citation: Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.
citation: Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, Imperatore G. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018 Jun 16;391(10138):2430-2440. doi: 10.1016/S0140-6736(18)30314-3. Epub 2018 May 18.
citation: Harding JL, Shaw JE, Peeters A, Davidson S, Magliano DJ. Age-Specific Trends From 2000-2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People. Diabetes Care. 2016 Jun;39(6):1018-26. doi: 10.2337/dc15-2308. Epub 2016 Apr 26.
citation: Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, Gregg EW. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021 Mar;9(3):165-173. doi: 10.1016/S2213-8587(20)30431-9. Epub 2021 Feb 4.